US 12,280,157 B2
Compositions and methods for inhibiting post-surgical adhesions
Andrew Wang, Chapel Hill, NC (US); and Yu Mi, Chapel Hill, NC (US)
Assigned to THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, Chapel Hill, NC (US)
Appl. No. 17/428,843
Filed by The University of North Carolina at Chapel Hill, Chapel Hill, NC (US)
PCT Filed Feb. 6, 2020, PCT No. PCT/US2020/017021
§ 371(c)(1), (2) Date Aug. 5, 2021,
PCT Pub. No. WO2020/163601, PCT Pub. Date Aug. 13, 2020.
Claims priority of provisional application 62/802,033, filed on Feb. 6, 2019.
Prior Publication US 2022/0125736 A1, Apr. 28, 2022
Int. Cl. A61K 9/51 (2006.01); A61K 31/573 (2006.01); A61P 41/00 (2006.01); B82Y 5/00 (2011.01)
CPC A61K 9/51 (2013.01) [A61K 31/573 (2013.01); A61P 41/00 (2018.01); B82Y 5/00 (2013.01)] 17 Claims
 
1. A method of treating a surgical site comprising:
contacting the surgical site with a particle formulation comprising targeting particles and scaffolding particles; wherein the targeting particles comprise poly(ethylene glycol)-poly(lactic-co-glycolic acid) copolymer and a collagen IV-targeting peptide; and the scaffolding particles comprise:
a core comprising poly(ethylene glycol)-poly(lactic-co-glycolic acid) copolymer; and
a shell, wherein the surface of the scaffolding particles comprise at least one diazirine group; and
UV-induced crosslinking the targeting particles and scaffolding particles to provide a composite membrane at the surgical site, wherein formation of post-surgical adhesions are inhibited by the composite membrane.